Summary: Pfizer, Inc.

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Pfizer, Inc.

  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • This company will be of major interest to investors in search of a high dividend stock.

Weaknesses: Pfizer, Inc.

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • One of the major weak points of the company is its financial situation.
  • The company's enterprise value to sales, at 3.63 times its current sales, is high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings Chart: Pfizer, Inc.

Source: Surperformance

ESG chart: Pfizer, Inc.

Source: Refinitiv

Add to a list
Composite Fundamentals Composite Valuation Composite Momentum Capi. ($)
167B
791B
595B
367B
315B
306B
247B
244B
218B
179B
Average 342.87B
Weighted average by Cap.
See all sector ratings
Investor Rating
Trading Rating
ESG Refinitiv
C+

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes